Abstract: Disclosed are two monoclonal antibodies, MAb52-29.1 and MAb52-25.1 mAbs, along with their fragments and derivatives, that recognize two conformational epitopes of human CD166 (ALCAM, 4F2), which are highly expressed on malignant tumors but weakly expressed or absent in normal human cells and tissues. This specificity enhances their potential as therapeutic agents while minimizing off-target effects. The anti-CD166 mAbs and their fragments and derivatives can be conjugated to cytotoxic drug moieties to form antibody-drug conjugates (ADCs), effectively inhibiting tumor growth in animal models and demonstrating potential for clinical applications.

Abstract: Disclosed is a monoclonal antibody, MAb52-4.2 mAb, and its fragments and derivatives that recognize a conformational epitope of human CD98hc (SLC3A2, 4F2HC), which is present highly on malignant tumors but weakly or is absent in normal human cells and tissues. This specificity enhances its potential as a therapeutic agent while minimizing off-target effects. The anti-CD98 hc mAb and its fragments and derivatives can be conjugated to cytotoxic drug moieties to form antibody-drug conjugates (ADCs), to inhibit tumor growth in animal models.

Abstract: Disclosed is a monoclonal antibody, MAb51-31 mAb, and its fragments and derivatives that recognize a conformational epitope of human integrin ?3/?1 (ITG?3/?1) complex, which is highly expressed on solid tumors but very low or absent in normal tissues. This specificity enhances its potential as a diagnostic and therapeutic agent while minimizing off-target effects. The anti-ITG?3/?1 mAb and its fragments and derivatives can be conjugated to cytotoxic drug moieties to form antibody-drug conjugates (ADCs), to inhibit tumor growth in human and animals.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing transferrin receptor 1 (TfR1) and its variants on the cell surface, including but not limited to AML, ALL, lymphoma, multiple myeloma, breast cancer, gastric cancer, glioblastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain and heavy chain variable regions of an anti-TfR1 monoclonal antibody (mAb), MAb11-22.1, which, is highly specific for tumor cells and in an ADC form, can functionally inhibit the proliferation of several human cancer cell lines and the growth of AML cell line-derived xenograft tumors in mouse models.

Abstract: Aspects of the disclosure relate to MUC18-binding proteins. Embodiments include methods for treating one or more conditions, for example cancer, using a MUC18-binding protein. In some embodiments, the disclosed methods and compositions involve one or more antibodies that are capable of binding MUC18.

Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing transferrin receptor 1 (TfR1) and its variants on the cell surface, including but not limited to AML, ALL, lymphoma, multiple myeloma, breast cancer, gastric cancer, glioblastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain and heavy chain variable regions of an anti-TfR1 monoclonal antibody (mAb), MAb11-22.1, which, is highly specific for tumor cells and in an ADC form, can functionally inhibit the proliferation of several human cancer cell lines and the growth of AML cell line-derived xenograft tumors in mouse models.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing podocalyxin-like protein precursor isoform 2 (PODXL-v2) and its variants with deletion of N-terminal serine and proline residues, on the cell surface, including gastric cancers, squamous cell carcinoma of the stomach, gastric adenocarcinoma, small cell carcinoma of the stomach, gastric squamous cell carcinoma, gastric carcinoid tumors, stomach and duodenal cancers, gliobastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain variable regions of an anti-PODXL-v2 monoclonal antibody (mAb), MAb1738, that can functionally inhibit the proliferation of several human cancer cell lines and the growth and metastasis of gastric cancer in mouse models.

Abstract: Provided herein are methods and reagents for increasing chemosensitivity to chemotherapy and immunotherapy in cancer patients. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an DKK3-neutralizing agent, such as a DKK3-neutralizing antibody provided herein. The methods can further include administering an effective amount of chemotherapy or immunotherapy to said patient.

Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing podocalyxin-like protein precursor isoform 2 (PODXL-v2) and its variants with deletion of N-terminal serine and proline residues, on the cell surface, including gastric cancers, squamous cell carcinoma of the stomach, gastric adenocarcinoma, small cell carcinoma of the stomach, gastric squamous cell carcinoma, gastric carcinoid tumors, stomach and duodenal cancers, gliobastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain variable regions of an anti-PODXL-v2 monoclonal antibody (mAb), MAI1738, that can functionally inhibit the proliferation of several human cancer cell lines and the growth and metastasis of gastric cancer in mouse models.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.